<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986037</url>
  </required_header>
  <id_info>
    <org_study_id>M10-378</org_study_id>
    <nct_id>NCT00986037</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety, tolerability and
      pharmacokinetics of ABT-308 in healthy volunteers and patients with mild to moderate
      controlled asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be determined by evaluation of adverse events, vital sign monitoring, physical examination, electrocardiograms, lung function and laboratory assessments.</measure>
    <time_frame>12 weeks after last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics will be determined by measuring serum concentration of ABT-308.</measure>
    <time_frame>12 weeks after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity will be determined by measuring serum concentrations of anti-ABT-308 antibodies.</measure>
    <time_frame>12 weeks after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>IV ABT-308 in asthmatics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-308 single escalating doses in mild to moderate asthmatics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC ABT-308 in asthmatics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-308 multiple SQ doses in mild to moderate asthmatics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV ABT-308 in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-308 single escalating IV doses in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-308</intervention_name>
    <description>Single IV doses</description>
    <arm_group_label>IV ABT-308 in asthmatics</arm_group_label>
    <arm_group_label>IV ABT-308 in healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-308</intervention_name>
    <description>Multiple SC doses x 3</description>
    <arm_group_label>SC ABT-308 in asthmatics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV dose</description>
    <arm_group_label>IV ABT-308 in asthmatics</arm_group_label>
    <arm_group_label>IV ABT-308 in healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple SC doses x 3</description>
    <arm_group_label>SC ABT-308 in asthmatics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers:

               1. A condition of good health based upon the results of medical history, physical
                  examination, vital signs, laboratory profile and ECG.

               2. BMI 18 to 29, inclusive.

          -  Mild asthma patients:

               1. Diagnosis of well-controlled, mild to moderate asthma by GINA guidelines for &gt; or
                  = to 6 months

               2. A condition of good health (than mild to moderate asthma) based upon the results
                  of medical history, physical examination, vital signs laboratory profile and EDG.

               3. BMI 18 to 34, inclusive.

        Exclusion Criteria:

          1. Asthma exacerbation within 8 weeks of Study Day 1.

          2. Clinically significant allergic reaction to any drug, biologic, food, or vaccine.

          3. History of allergic reaction or significant sensitivity to constituents of study drug.

          4. Receipt of any investigational product within 30 days or 5 half-lives (whichever is
             longer) prior to study drug administration.

          5. Subject is a smoker or has a history of smoking within the 6-month period preceding
             study drug administration.

          6. Current enrollment in another clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Campbell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Tripp CS, Cuff C, Campbell AL, Hendrickson BA, Voss J, Melim T, Wu C, Cherniack AD, Kim K. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. Adv Ther. 2017 Jun;34(6):1364-1381. doi: 10.1007/s12325-017-0525-8. Epub 2017 Apr 28.</citation>
    <PMID>28455782</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <name_title>Catherine Tripp MD PhD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Adverse events</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

